Table 3 PIK3CA mutation status according to hormone receptor and ERBB2 status and relation to metastasis-free survival
From: PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Number of patients | 5-year MFS | HR (95% CI) | Pvaluea | |
|---|---|---|---|---|
Total population | 452 | |||
Wild-type | 301 | 69.6% | 1 | 0.0056 |
Mutated | 151 | 81.0% | 0.62 (0.44-0.87) | |
ERα+ | 335 | |||
Wild-type | 204 | 75.6% | 1 | NS |
Mutated | 131 | 81.9% | 0.71 (0.49-1.04) | |
ERα- | 117 | |||
Wild-type | 97 | 56.9% | 1 | NS |
Mutated | 20 | 75.0% | 0.46 (0.18-1.15) | |
PR+ | 258 | |||
Wild-type | 151 | 77.8% | 1 | 0.0064 |
Mutated | 107 | 86.6% | 0.52 (0.33-0.83) | |
PR- | 194 | |||
Wild-type | 150 | 61.3% | 1 | NS |
Mutated | 44 | 67.6% | 0.91 (0.55-1.50) | |
ERBB2+ | 101 | |||
Wild-type | 76 | 59.9% | 1 | 0.014 |
Mutated | 25 | 88.0% | 0.31 (0.12-0.79) | |
ERBB2- | 351 | |||
Wild-type | 225 | 72.9% | 1 | NS |
Mutated | 126 | 79.7% | 0.75 (0.51-1.08) |